Marcelo Páez-Pereda

Ipsen (France) — France

Medicine · Health Sciences

41h-index4.9kcitations147works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pituitary Gland Disorders and Treatments(55), Growth Hormone and Insulin-like Growth Factors(21), Stress Responses and Cortisol(18), Adrenal Hormones and Disorders(17), Neuroendocrine Tumor Research Advances(16)

Publications147 total

A novel computational framework to identify translational potential of genetic mouse models in rare genetic obesity
2025Open Access
Figure S5 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S3 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S7 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S8 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S3 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S7 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S8 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S5 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S4 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S6 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S1 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S1 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S4 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Figure S6 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Günter K. Stalla(31), Eduardo Arzt(31), Herta Flor(18), Ulrich Renner(17), Marily Theodoropoulou(11), Johanna Stalla(8), Damiana Giacomini(8), Damián Refojo(7), Alberto Chervín(7), Alberto Carbia Nagashima(6), Carolina Perez Castro(6), Marta Labeur(6), Juan Gerez(5), Marco Losa(5), Victoria Goldberg(5), Felix Hausch(5), Damián Kovalovsky(4), Uberto Pagotto(4), Úrsula Hopfner(4), Johannes M. H. M. Reul(4)